CLINICAL IMPLICATIONS OF TUMOR ASSOCIATED PROTEASES DETERMINATIONIN THE TUMORS AND BLOOD PLASMA OF COLORECTAL CANCER PATIENTS
Associations between matrix metalloproteinase (MMP) 2, 7, 9, tissue MMP inhibitor TIMP-1 and plasminogen activation system
components (uPA, tPA and PAI-1) plasma and/or tumor levels in colorectal cancer (CRC) patients were evaluated in order to reveal their
potential clinical implications. Two groups of CRC patients monitored for 5 or 10 years were enclosed in the study. Earlier, corresponding
markers’ levels were measured in their plasma and/or tumors by immunoenzymatic techniques. High tumor PAI-1 (≥4,0 ng/mg protein)
was demonstrated to be a significant, but not independent unfavorable prognostic factor for 5 and 10 years overall survival. Its role was
mostly pronounced in stage III patients. High preoperative plasma MMP-7 and TIMP-1 levels (cut-offs – 4,0 and 347 ng/ml respectively)
were shown to be independent unfavorable prognostic factors, and univariate analysis revealed unfavorable prognostic value of high tumor
MMP-7 content (≥7,8 ng/mg protein) in patients with disseminated process.
Keywords:
urokinase type plasminogen activator (uPA), tissue type plasminogen activator (tPA), type 1 plasminogen activator inhibitor
(PAI-1), matrix metalloproteinase 2, matrix metalloproteinase 7, matrix metalloproteinase 9, tissue matrix metalloproteinase inhibitor 1, colorectal cancer, prognosis